Bank of New York Mellon Corp - BIOMARIN PHARMACEUTICAL INC ownership

BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of BIOMARIN PHARMACEUTICAL INC
ValueSharesWeighting
Q1 2023$975,869
+267.1%
950,000
+280.0%
0.00%
Q4 2022$265,828
-42.1%
250,000
-45.8%
0.00%
Q3 2022$459,000
+3.1%
461,000
+2.4%
0.00%
Q2 2022$445,000
-1.8%
450,0000.0%0.00%
Q1 2022$453,000
-4.2%
450,0000.0%0.00%
Q4 2021$473,000
-45.8%
450,000
-47.1%
0.00%
Q3 2021$873,000
-1.4%
850,0000.0%0.00%
Q2 2021$885,000
+1.7%
850,0000.0%0.00%
Q1 2021$870,000
-5.0%
850,0000.0%0.00%
Q4 2020$916,000
+3.2%
850,0000.0%0.00%
Q3 2020$888,000
-14.9%
850,0000.0%0.00%
Q2 2020$1,043,000
+121.9%
850,000
+88.9%
0.00%
Q1 2020$470,000
-48.3%
450,000
-47.6%
0.00%
Q4 2019$909,000
+7.4%
858,0000.0%0.00%
Q3 2019$846,000
-5.2%
858,0000.0%0.00%
Q2 2019$892,000
+1.1%
858,0000.0%0.00%
Q1 2019$882,000
+4.6%
858,000
+0.9%
0.00%
Q4 2018$843,000
-6.9%
850,0000.0%0.00%
Q3 2018$905,000850,0000.00%
Other shareholders
BIOMARIN PHARMACEUTICAL INC shareholders Q4 2020
NameSharesValueWeighting ↓
SHENKMAN CAPITAL MANAGEMENT INC 30,138,000$29,510,0003.72%
PFM Health Sciences, LP 45,910,000$46,002,0001.72%
Cheyne Capital Management (UK) LLP 2,320,000$2,330,0001.47%
ADVENT CAPITAL MANAGEMENT /DE/ 41,077,000$41,277,0000.66%
SSI INVESTMENT MANAGEMENT LLC 9,071,000$9,068,0000.50%
PALISADE CAPITAL MANAGEMENT, LP 14,548,000$14,612,0000.34%
RWC Asset Management LLP 7,500,000$7,552,0000.21%
KBC Group NV 400,000$40,316,0000.15%
PROSPECTOR PARTNERS LLC 1,000,000$1,000,0000.12%
MACKAY SHIELDS LLC 11,822,000$11,816,0000.10%
View complete list of BIOMARIN PHARMACEUTICAL INC shareholders